Every medicine has a story. For nucleic acid therapeutics, drugs based on DNA or RNA molecules, the journey is both complex and inspiring. Starting with a scientific idea in a laboratory, it grows step by step into a treatment to change patients’ lives.
Let’s take a closer look at the major stages in this journey, from the bench to the bedside.
It all begins with a scientific insight. Researchers identify a genetic target, for example, a faulty gene or RNA sequence that drives a disease. Using the language of nucleotides, they design a short DNA or RNA strand, called an oligonucleotide, to specifically interact with that target.
At this early stage, the goal is proof of concept: Showing that the idea can take effect in cells or in small-scale experiments.
Once a candidate looks promising, it moves into preclinical testing. Scientists study how the therapeutic behaves in biological systems, checking for safety, stability, and efficiency. At the same time, chemists refine the oligonucleotide’s design to improve its performance, for instance, by adding chemical modifications that increase stability.
Designing a therapeutic is one thing, making enough of it at the required quality is another. Here, CDMOs like BioSpring play a crucial role. We help to translate lab-scale synthesis into robust, scalable manufacturing processes, all under strict GMP (Good Manufacturing Practice) standards.
This step ensures that every batch of the therapeutic meets the highest standards of purity and consistency.
If preclinical studies are successful, the therapeutic enters clinical trials. These take place in three main phases:
Phase I: Safety – testing in small groups of healthy volunteers or patients
Phase II: Efficacy – determining if the therapeutic works as intended in patients
Phase III: Large-scale confirmation – demonstrating safety and effectiveness in
Each phase brings the therapeutic closer to regulatory approval.
Agencies such as the FDA (Food and Drug Administration) or EMA (European Medicines Agency) carefully evaluate the data. Only when they are satisfied that the therapeutic is safe, effective, and manufactured to the highest quality standards is it approved for use.
The ultimate destination: the patient’s bedside. What began as an idea in a laboratory becomes a therapy that can transform lives. For patients with rare genetic disorders or conditions once thought untreatable, nucleic acid therapeutics bring new hope.
Why it matters
The journey from bench to bedside is long and complex but it is also the heart of medical innovation. At BioSpring, we are proud to contribute to this journey by providing expertise, infrastructure, and passion needed to bring nucleic acid therapeutics from concept to reality.
By moving the elements of life, we help ensure that groundbreaking science makes its way where it matters most – to the patients who need it.